Torsemide: Nursing Drug Guide, Electrolyte Depletion & Hold Rules
Once-daily oral loop diuretic for edema and hypertension: the bedside priority is electrolyte and volume depletion—hypokalemia (especially with digoxin on the MAR), hyponatremia, hypomagnesemia, dehydration, and hypotension when diuresis outpaces intake. Labeling contraindicates anuria and hypersensitivity to torsemide or sulfonylureas; hold for oliguria, falling potassium, or prerenal azotemia and restart only after the team corrects imbalance.
Labeling warns that patients on diuretics may develop electrolyte imbalance, hypovolemia, or prerenal azotemia with thirst, weakness, hypotension, oliguria, and tachycardia. Excessive diuresis may cause dehydration, blood-volume reduction, and thromboembolism risk in older adults. In cardiovascular patients—especially those on digitalis—hypokalemia increases arrhythmia risk because digitalis may exaggerate myocardial effects of hypokalemia. If imbalance occurs, discontinue torsemide until corrected, then restart at a lower dose. Tinnitus and hearing loss have been reported after oral torsemide; ototoxicity risk also exists with other loop diuretics and aminoglycosides.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every dose, review the latest basic metabolic panel, daily weight, and intake and output. Hold torsemide when potassium is low, the patient is anuric or oliguric, or creatinine rises with prerenal azotemia—then notify the prescriber or pharmacist. Pair diuresis with edema assessment and teach patients to report cramps, palpitations, and dizziness on standing.
Most common brand names
Demadex is a widely recognized U.S. brand for torsemide tablets. Generic torsemide is available in 5 mg, 10 mg, 20 mg, and 100 mg oral strengths per reviewed labeling. Verify tablet strength on every pass—these strengths are not interchangeable without a prescriber order.
Many heart failure regimens combine torsemide with spironolactone or another aldosterone antagonist; hepatic cirrhosis labeling directs co-administration with an aldosterone antagonist or potassium-sparing diuretic. Confirm intentional combination therapy before questioning duplicate diuretics.
Why we give it — Indications
U.S. prescribing information lists torsemide tablets for edema associated with congestive heart failure, renal disease, or hepatic disease—including edema with chronic kidney disease. It is also indicated for hypertension alone or in combination with other antihypertensive agents.
| Use | Detail |
|---|---|
| Edema / fluid overload | CHF, renal disease, or hepatic disease; titrate to minimal effective dose; watch for over-diuresis |
| Chronic renal failure | Labeling notes effectiveness for edema with chronic renal failure; higher doses may be needed when renal clearance is reduced |
| Hypertension (oral) | Usual initial 5 mg once daily; may increase to 10 mg; add another agent if 10 mg is insufficient |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Torsemide inhibits the Na+/K+/2Cl− carrier in the thick ascending limb of the loop of Henle, increasing urinary excretion of sodium, chloride, and water without significantly altering glomerular filtration rate per labeling. With oral dosing, diuresis begins within 1 hour, peaks during the first or second hour, and lasts about 6 to 8 hours. Bioavailability is approximately 80%; food delays time to peak by about 30 minutes but does not change overall diuretic effect. Expect potassium and magnesium losses—especially with higher edema doses, cirrhosis, brisk diuresis, or corticosteroid co-therapy.
Dosing overview
Individualize to the minimal dose that achieves the diuretic goal. Titrate upward by approximately doubling until response is adequate. Single doses above labeled maximums have not been adequately studied for each indication.
Renal impairment: Diuretic response may require higher doses because less drug reaches the luminal site; total clearance may remain near normal because hepatic metabolism persists per labeling.
Hepatic impairment: Use caution in cirrhosis with ascites; initiate diuresis in hospital because sudden fluid/electrolyte shifts may precipitate hepatic coma. Co-administer aldosterone antagonist or potassium-sparing drug to prevent hypokalemia and metabolic alkalosis.
Pediatrics: Safety and effectiveness not established in pediatric patients per labeling.
Missed dose: Not specified in the reviewed prescribing information; follow prescriber or pharmacy guidance.
Onset, peak, and duration
- Oral onset: Diuresis within 1 hour; peak first or second hour; duration 6–8 hours
- Bioavailability: Approximately 80% with little intersubject variation
- Food: Delays time to peak by ~30 minutes; AUC and diuretic activity unchanged
- Half-life: Approximately 3.5 hours in healthy adults; prolonged in decompensated CHF and hepatic cirrhosis per labeling
- Timing: May be given any time relative to meals per labeling
Before you give it — Safety check
Pretreatment checks
- Latest BMP: potassium, sodium, chloride, bicarbonate/CO2, creatinine, BUN, glucose
- Baseline weight, blood pressure, and orthostatic vitals when diuresis is aggressive
- Confirm patient is not anuric (contraindicated); review allergies to torsemide and sulfonylureas (angioedema reported in sulfa-allergic patients per labeling)
- Review interacting drugs: digoxin, ACE inhibitors/ARBs, NSAIDs/salicylates, aminoglycosides, lithium, cholestyramine, probenecid
Contraindications
- Known hypersensitivity to torsemide or sulfonylureas
- Anuria
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Digoxin | Diuretic-induced hypokalemia may increase arrhythmia risk; digitalis may exaggerate myocardial effects of hypokalemia; digoxin coadministration increases torsemide AUC ~50% without mandatory dose adjustment per labeling | Trend potassium and rhythm; hold torsemide for symptomatic hypokalemia |
| ACE inhibitors / ARBs | Commonly co-prescribed; monitor for hypotension and rising creatinine when therapy changes | Assess BP, orthostatics, and renal function after dose adjustments |
| NSAIDs / indomethacin | Indomethacin partially inhibits natriuretic effect; NSAID coadministration with loop diuretics has occasionally been associated with renal dysfunction | Assess edema and creatinine trends; teach patients to avoid hidden OTC NSAIDs unless approved |
| Salicylates (high dose) | Compete for renal tubular secretion—salicylate toxicity possible when torsemide is coadministered | Screen aspirin/NSAID use; notify prescriber if salicylate toxicity signs emerge |
| Aminoglycosides | Other loop diuretics increase ototoxic potential with aminoglycosides—potential interaction with torsemide not studied but caution applies | Monitor for tinnitus/hearing change; coordinate renal-dosing with pharmacy |
| Lithium | Diuretics reduce lithium clearance—high toxicity risk; torsemide-lithium combination not studied | Clarify lithium levels and hold parameters with prescriber/pharmacist |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Oral tablets: 5, 10, 20, and 100 mg strengths per reviewed U.S. labeling. Tablets may be given at any time in relation to meals. No special elderly dosage adjustment is required per labeling—still monitor for over-diuresis.
- Verify correct tablet strength (5 vs 10 vs 20 vs 100 mg) with independent double-check when available
- Many regimens use once-daily morning dosing to limit nocturia—follow MAR exactly
- Food delays peak by ~30 minutes without reducing overall effect—document if given with meals for trend analysis
- Separate cholestyramine from torsemide—labeling recommends against simultaneous administration (cholestyramine decreased oral absorption in animal studies; human interaction not studied)
- Pair each dose with accurate urinary output measurement and orthostatic blood pressure checks when diuresis is brisk
Torsemide potency and pharmacokinetics differ from furosemide and bumetanide. Never convert loop diuretic orders without pharmacist verification. Tinnitus and reversible hearing loss have been observed after oral torsemide per labeling—document auditory symptoms.
Expected therapeutic response
- Increased urine output within expected onset window for route given
- Decrease in edema, weight, or pulmonary congestion symptoms when treating fluid overload in heart failure
- Blood pressure reduction when used for hypertension (monitor for excessive drop when combined with other antihypertensives)
Red flags — Stop and act
Electrolyte loss and volume depletion can progress quickly—especially with dose escalation, combination diuretics, or inadequate oral intake.
- Potassium below prescriber or protocol hold limit, new PVCs or ventricular ectopy, or digoxin on the MAR with falling K+
- Oliguria, anuria, acute weight loss, orthostatic hypotension, or confusion suggesting hypovolemia or prerenal azotemia
- Marked rise in BUN/creatinine with dehydration symptoms—labeling directs discontinuation until corrected
- New tinnitus or hearing loss after torsemide (oral or parenteral loop diuretic exposure)
- Muscle cramps, weakness, or palpitations with electrolyte depletion on electrolyte panel review
- Angioedema, serious skin reaction (Stevens-Johnson syndrome/toxic epidermal necrolysis reported postmarketing), or pancreatitis (reported postmarketing)
Adverse effects
| Adverse effect | Notes (labeling) | Nursing response |
|---|---|---|
| Electrolyte imbalance | Hypokalemia, hyponatremia, hypochloremic alkalosis, hypomagnesemia, hypocalcemia | Trend BMP; hold dose and notify team for symptomatic or protocol-level abnormalities |
| Volume depletion | Dehydration, hypotension, orthostatic hypotension (aggravated by alcohol, barbiturates, narcotics) | Orthostatic vitals; fall precautions; assess I&O and weight |
| Ototoxicity | Tinnitus and hearing loss (usually reversible) reported after oral torsemide; also reported with rapid IV loop diuretics | Hold and notify prescriber; document timing and concurrent ototoxic drugs |
| GI effects | Nausea, vomiting, diarrhea, constipation, pancreatitis (reported) | Supportive care; differentiate from electrolyte-related GI symptoms |
| Hepatic coma risk | Sudden fluid/electrolyte shifts in cirrhosis with ascites may precipitate hepatic coma | Initiate in hospital per labeling; monitor mental status; use potassium-sparing co-therapy |
| Hyperglycemia / glycosuria | Altered glucose tolerance; rarely precipitation of diabetes mellitus | Monitor glucose in diabetic patients per labeling |
| Hypersensitivity / dermatologic | Rash, urticaria, photosensitivity; SJS/TEN reported | Discontinue at first sign of serious skin reaction; escalate urgently |
On a small screen, swipe or scroll sideways to see the full table.
Common placebo-controlled adverse reactions (>1%) included headache, excessive urination, dizziness, asthenia, diarrhea, nausea, and ECG abnormality per labeling. Discontinue therapy when moderate or severe reactions occur and restart only after correction at a lower dose when appropriate.
Overdose, toxicity, and antidote
There is no human experience with torsemide overdose in labeling; anticipated signs are excessive pharmacologic effects: dehydration, hypovolemia, hypotension, hyponatremia, hypokalemia, hypochloremic alkalosis, and hemoconcentration.
Antidote
Not specified in the reviewed prescribing information — no specific reversing agent is listed. Treatment is supportive fluid and electrolyte replacement.
Management per labeling
- Replace fluid and electrolyte losses with close monitoring of hemodynamics and serum electrolytes
- Serum torsemide levels are not widely available for overdose assessment
- No data support urine pH manipulation to accelerate elimination
- Torsemide is not dialyzable—hemodialysis will not accelerate elimination per labeling
- Coordinate potassium and magnesium replacement per prescriber orders—often potassium chloride when safe
- Contact local poison control or medical toxicology services per facility protocol for significant overdose or instability
Look-alike / sound-alike and error prevention
- Torsemide vs furosemide vs bumetanide — loop diuretics with different mg potency and duration; never convert doses without pharmacist verification (compare names on MAR and blister packs)
- Demadex brand name — verbal orders may be misheard as furosemide/Lasix; confirm generic name torsemide and strength in writing
- 5 mg vs 10 mg vs 20 mg vs 100 mg tablets — quadruple-check strength; 100 mg tablets are especially high-risk if confused with lower strengths
- Once-daily scheduling — duplicate doses from MAR and home medication lists; perform medication reconciliation at admission, transfer, and discharge
- Sulfonylurea allergy cross-check — contraindicated in sulfonylurea hypersensitivity; verify allergy history before first dose
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Best timing | Once-daily morning dose is common; follow MAR—food only shifts peak ~30 min |
| Daily weights | Same scale, same time, similar clothing—critical for heart failure diuresis and dependent edema trends |
| CHF clearance | Total clearance ~50% of healthy volunteers in decompensated CHF—may need dose titration with close monitoring |
| Cholestyramine | Do not give simultaneously—may reduce absorption; coordinate timing with pharmacy |
| Gout flare | Symptomatic gout reported—monitor uric acid trends when relevant |
| Ask pharmacy when | Loop diuretic conversion questions, oliguria with rising creatinine, lithium co-therapy, or suspected overdose |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Older adults | Included in trials without specific age-related safety differences; still higher risk of dehydration, hypotension, and thromboembolism with excessive diuresis |
| Hepatic cirrhosis / ascites | Initiate in hospital; sudden fluid/electrolyte shifts may precipitate hepatic coma; co-administer aldosterone antagonist or potassium-sparing diuretic per labeling |
| Renal failure | Higher doses may be needed in nonanuric renal failure; seizures reported in acute renal failure studies at very high loop diuretic doses—follow prescriber limits |
| Diabetes mellitus | Hyperglycemia reported; mean glucose increases seen in hypertension trials—monitor glucose in diabetes |
| Pregnancy | Pregnancy Category B; adequate human studies not conducted—use during pregnancy only if clearly needed per labeling |
| Lactation | Not known whether excreted in human milk; many drugs are excreted in milk—use caution when administering to nursing women |
| Pediatrics | Safety and effectiveness not established; premature infant loop-diuretic risks described for other agents—not studied for torsemide |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Serum electrolytes (especially potassium), CO2, creatinine, and BUN—frequently during first months and periodically thereafter per labeling
- Weight, I&O, blood pressure, and orthostatic vitals during active diuresis
- Telemetry or rhythm assessment when digoxin is co-prescribed and potassium is trending down
- Glucose in diabetic patients; magnesium and calcium periodically per labeling
- Signs of ototoxicity (tinnitus, hearing change), especially with aminoglycosides or high loop-diuretic exposure
Document
- Dose, route, time, indication, urine output response, and weight change
- Latest BMP values and any hold parameters triggered
- Tablet strength verified (5/10/20/100 mg) and hold parameters triggered
- Patient teaching on cramps, dizziness, daily weights, and when to report symptoms
Patient teaching
- Report muscle cramps, weakness, dizziness on standing, palpitations, or decreased urination promptly
- Weigh yourself daily at the same time with similar clothing if instructed for heart failure management
- Do not take OTC NSAIDs or appetite suppressants without asking your prescriber—they can reduce diuretic effect or harm kidneys
- Take potassium supplements or eat high-potassium foods only as directed; do not self-treat low potassium
- Report ringing in the ears or hearing changes—these have been reported with torsemide
- Rise slowly from sitting or lying down to reduce orthostatic dizziness
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Known torsemide or sulfonylurea allergy, angioedema, or serious skin reaction
- Anuria (contraindicated) or oliguria without prescriber-directed plan
- Potassium, magnesium, or sodium below institutional hold parameters or symptomatic electrolyte depletion
- Symptomatic hypotension, orthostatic presyncope, or acute mental status change suggesting hypovolemia or prerenal azotemia
- Fluid/electrolyte imbalance per labeling—discontinue until corrected; do not restart at prior dose without prescriber review
- New tinnitus or hearing change after torsemide, especially with concurrent aminoglycoside
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Torsemide is often chosen for once-daily oral regimens in heart failure—but electrolyte injury still happens when nurses skip BMP trends, sulfonamide allergy checks, and hold rules during brisk diuresis.
1. Check-before-you-give protocol
- Right patient, drug, dose, route, time—and correct tablet strength (5/10/20/100 mg)
- Latest BMP within protocol window; compare weight and net I&O to diuresis goals
- Confirm patient is not anuric; screen torsemide and sulfonylurea allergies
- Scan MAR for digoxin, ACE inhibitor, NSAID/salicylate, lithium, and aminoglycoside overlap
2. High-alert and safety badge
Not on all institutional high-alert lists, but loop-diuretic electrolyte and volume risk requires BMP, I&O, anuria screening, and hold discipline comparable to high-alert drugsLabeling directs discontinuation when electrolyte imbalance, hypovolemia, or prerenal azotemia develop—restart only after correction, usually at a lower dose.
3. Clinical workflow: hold and question rules
- If potassium is falling across shifts, hold the next dose and notify prescriber/pharmacist before giving another loop diuretic
- If urine output drops while diuresis continues, clarify whether therapy is helping or harming renal perfusion
- Question any order to substitute torsemide for furosemide mg-for-mg without pharmacy conversion
4. Critical teach-back questions
- “What symptoms should you report right away while taking this water pill?” (Patient should name cramps, palpitations, dizziness, decreased urination, or ringing in the ears.)
- “How will you track whether the diuretic is working safely at home?” (Patient should describe daily weights, fluid limits if ordered, and calling the team for rapid weight gain or loss.)
5. Care coordination
Pharmacist: Loop diuretic conversion, digoxin/lithium/NSAID interactions, cholestyramine timing, and electrolyte replacement protocols
Prescriber: Notify for refractory edema, anuria/oliguria, symptomatic hypokalemia with digoxin, ototoxicity symptoms, or cirrhosis patients with mental status change during diuresis
🧠 Quick mental checklist
- What is the latest potassium—and is digoxin on the MAR?
- Is the patient anuric or oliguric before I give this dose?
- Did I verify 5 vs 10 vs 20 vs 100 mg tablet strength?
- Does net I&O and weight match the prescriber’s diuresis goal?
- Did I teach the patient what cramps, dizziness, and tinnitus mean?
Torsemide NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for torsemide with a tabbed heart-failure case (MAR, labs, I&O, nursing notes), then priority action, cue-recognition SATA, electrolyte trend SATA, matrix urgency sorting, safe oral administration judgment, and overdose cloze—including evaluate outcomes after the prescriber holds diuresis.
Select a tab to view MAR, labs, I&O, and nursing note details for this case.
- Torsemide 20 mg PO daily — scheduled 0800 (given yesterday; due now)
- Digoxin 0.125 mg PO daily — given 0700
- Lisinopril 10 mg PO daily — given 0700
- Spironolactone 25 mg PO daily — given 0700
- Home torsemide 20 mg daily continued from admission list
- Admission K+ 4.0 mEq/L; yesterday 3.4; today 3.1 mEq/L (BMP 0730)
- Magnesium 1.6 mg/dL
- Creatinine 1.1 → 1.32 mg/dL over 48 h; BUN 24 → 36 mg/dL
- Urine output 3.2 L; intake 1.5 L — net negative ~1.7 L
- Weight 81.4 kg → 80.1 kg in 48 h
- Orthostatics: lying BP 116/70; standing BP 98/60 with dizziness reported
- 68-year-old with HFrEF; mild crackles decreased after two days of torsemide
- 0745: leg cramps; patient dizzy standing for AM hygiene
- Telemetry: increased PVCs since 0700
- 0800: nurse preparing 20 mg torsemide tablet—reviewing case tabs first
Answer key & rationale
Frequently asked questions
What should I check before giving torsemide?
Review the latest basic metabolic panel (especially potassium, sodium, magnesium, creatinine, and BUN), compare weight and intake/output to diuretic goals, assess blood pressure and orthostatic symptoms, confirm the patient is not anuric, and verify allergies to torsemide or sulfonylureas plus interacting drugs such as digoxin, ACE inhibitors, NSAIDs, salicylates, and lithium. Match the ordered oral dose and tablet strength (5, 10, 20, or 100 mg) to the MAR before administration.
When should nurses hold torsemide?
Hold and contact the prescriber or pharmacist when potassium or magnesium is below protocol limits, the patient has symptomatic hypotension or orthostasis, urine output is inadequate (oliguria or anuria), creatinine or BUN rises sharply with prerenal azotemia during diuresis, the patient reports new tinnitus or hearing change, or there is known hypersensitivity to torsemide or sulfonylureas. Labeling directs discontinuation until fluid and electrolyte imbalance is corrected; do not restart at the same dose without clarification.
Why is hypokalemia dangerous with torsemide and digoxin?
Torsemide increases urinary sodium, chloride, and water loss through loop diuresis. Labeling states that in patients receiving digitalis glycosides, diuretic-induced hypokalemia may be a risk factor for arrhythmias because digitalis may exaggerate the metabolic effects of hypokalemia, especially myocardial effects. Nurses should trend potassium with BMP monitoring, watch telemetry when ordered, and hold torsemide for symptomatic or protocol-level hypokalemia while notifying the team.
How does torsemide differ from furosemide at the bedside?
Both are loop diuretics, but reviewed torsemide labeling is for oral tablets with once-daily dosing in many regimens, approximately 80% bioavailability, and a longer elimination half-life (about 3.5 hours) than furosemide. Potency and milligram doses are not interchangeable—always verify orders with pharmacy. Torsemide is contraindicated in anuria and in patients allergic to torsemide or sulfonylureas.
Is there an antidote for torsemide overdose?
No human overdose experience and no specific antidote are described in the reviewed prescribing information. Anticipated effects are exaggerated pharmacologic action: dehydration, hypovolemia, hypotension, hyponatremia, hypokalemia, and hypochloremic alkalosis. Treatment is fluid and electrolyte replacement; torsemide is not dialyzable. Contact local poison control or medical toxicology services per facility protocol for significant overdose.
References
- U.S. National Library of Medicine. TORSEMIDE tablet — SPL product labeling (AvPAK). DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1439b9c-c01c-a6d4-594b-d92b8e0af26e
- U.S. National Library of Medicine. DEMADEX (torsemide) tablet — SPL product labeling. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aff713e8-2cb6-4e49-94a2-c55c5491c822
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.